Yang, H.; Liu, B.; Liu, D.; Yang, Z.; Zhang, S.; Xu, P.; Xing, Y.; Kutschick, I.; Pfeffer, S.; Britzen-Laurent, N.;
et al. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Cancers 2022, 14, 3152.
https://doi.org/10.3390/cancers14133152
AMA Style
Yang H, Liu B, Liu D, Yang Z, Zhang S, Xu P, Xing Y, Kutschick I, Pfeffer S, Britzen-Laurent N,
et al. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Cancers. 2022; 14(13):3152.
https://doi.org/10.3390/cancers14133152
Chicago/Turabian Style
Yang, Hai, Bin Liu, Dongxue Liu, Zhirong Yang, Shuman Zhang, Pengyan Xu, Yuming Xing, Isabella Kutschick, Susanne Pfeffer, Nathalie Britzen-Laurent,
and et al. 2022. "Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer" Cancers 14, no. 13: 3152.
https://doi.org/10.3390/cancers14133152
APA Style
Yang, H., Liu, B., Liu, D., Yang, Z., Zhang, S., Xu, P., Xing, Y., Kutschick, I., Pfeffer, S., Britzen-Laurent, N., Grützmann, R., & Pilarsky, C.
(2022). Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Cancers, 14(13), 3152.
https://doi.org/10.3390/cancers14133152